8-K: Ocugen Announces Positive Clinical Data and Outlines Path to Potential BLA Filings

Ocugen reports fourth quarter and full year 2024 financial results, highlighting progress in gene therapy programs and alignment with the FDA on a pivotal trial for Stargardt disease.

Summary

• Ocugen announced its fourth quarter and full year 2024 financial results, along with business updates on March 5, 2025.
• The company is focused on developing gene therapies for blindness diseases.
• A key highlight is the alignment with the FDA on a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease, potentially expediting clinical development by two to three years.
• Dosing has been completed in the OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA), with favorable safety and tolerability profiles observed.
• Two-year data from the Phase 1/2 clinical trial of OCU400 for retinitis pigmentosa (RP) demonstrated a durable and statistically significant (p=0.005) improvement in visual function.
• OCU400 is on track to meet 1H 2025 recruitment completion and potential BLA/MAA filings by mid-2026.
• The company secured $65 million in equity/debt financings in the second half of 2024 to extend the cash runway into the first quarter of 2026.
• Ocugen anticipates three potential BLA filings in the years 2026, 2027, and 2028 for RP, Stargardt, and GA treatments, respectively.
• The company's cash and restricted cash totaled $58.8 million as of December 31, 2024, compared to $39.5 million as of December 31, 2023.
• Ocugen reported a net loss per common share of $0.05 for the three months ended December 31, 2024, compared to a $0.04 net loss per common share for the three months ended December 31, 2023.
• For the year ended December 31, 2024, Ocugen reported a net loss per common share of $0.20, compared to a $0.26 net loss per common share for the year ended December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant clinical progress, FDA alignment, and a clear path to potential BLA filings. The secured financing also contributes to a favorable sentiment.

Positives

• Alignment with the FDA on the OCU410ST trial accelerates the development timeline and potentially saves costs.
• Favorable safety and tolerability profiles observed in the OCU410 ArMaDa clinical trial for GA.
• OCU400 shows durable and statistically significant improvement in visual function for RP patients.
• OCU400 is on track for BLA/MAA filings by mid-2026.
• The company secured $65 million in financing, extending the cash runway into the first quarter of 2026.
• The IND application for OCU500, the inhaled mucosal vaccine for COVID-19, was cleared by the FDA.
• The EMA granted OMPD for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19 (RP19), and cone-rod dystrophy 3 (CORD3).
• The EC provided a positive opinion from the EMAs CAT for OCU400, OCU410, and OCU410ST Advanced Therapy Medicinal Product (ATMP) classification.

Negatives

• The company reported a net loss per common share of $0.05 for the three months ended December 31, 2024, compared to a $0.04 net loss per common share for the three months ended December 31, 2023.
• The company reported a net loss per common share of $0.20 for the year ended December 31, 2024, compared to a $0.26 net loss per common share for the year ended December 31, 2023.

Risks

• The success of clinical trials is subject to numerous factors, and preliminary results may not be indicative of final data.
• Unfavorable new clinical trial data may emerge.
• Clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities.
• The company's ability to achieve its anticipated BLA filing timelines is subject to regulatory and clinical trial risks.

Future Outlook

Ocugen anticipates three potential BLA filings in the years 2026, 2027, and 2028 for RP, Stargardt, and GA treatments, respectively, and estimates that its current cash, cash equivalents, and investments will enable it to fund its operations into the first quarter of 2026.

Management Comments

• 'Ongoing data from all three clinical programs, along with patient testimonials, continue to support the benefit of one-time treatment from our revolutionary modifier gene therapy platformas we are seeing consistent stabilization or improvement in treated eyes while maintaining a favorable safety and tolerability profile,' said Dr. Shankar Musunuri, Chairman, CEO and Co-founder of Ocugen.
• 'Throughout 2024, the Company continually advanced its clinical programs in line with enrollment and dosing timelines, and we will continue to drive the product pipeline forward in 2025,' said Dr. Shankar Musunuri, Chairman, CEO and Co-founder of Ocugen.
• 'Meaningful progress in 2024 and recent success with FDA brought us closer to our goal of three potential BLAs in the years2026, 2027, 2028, encompassing RP, Stargardt and GA treatments, respectively,' said Dr. Musunuri.
• 'I am extremely proud of our team at Ocugen, who are working tirelessly to enroll patients across all four clinical programs in close collaboration with the study centers and investigators,' said Dr. Huma Qamar, Chief Medical Officer at Ocugen.
• 'It is very gratifying to think about the potential unmet medical need that can be addressed through modifier therapy for patients who currently have no options and are facing the prospects of losing their vision altogether,' said Dr. Huma Qamar, Chief Medical Officer at Ocugen.

Industry Context

Ocugen is operating in the competitive gene therapy space, focusing on addressing unmet needs in blindness diseases. The company's progress with its modifier gene therapy platform and regulatory achievements position it as a potential player in the market.

Comparison to Industry Standards

• The 52% slower lesion growth in treated eyes versus untreated fellow eyes in the OCU410ST GARDian clinical trial compares favorably to existing treatments for Stargardt disease, where available.
• The clinically meaningful 2-line (10-letter) improvement in visual function (BCVA) in treated eyes in the OCU410ST GARDian clinical trial is a positive indicator compared to standard outcomes in untreated patients.
• The absence of serious adverse events in the OCU410 ArMaDa clinical trial, including no cases of ischemic optic neuropathy, vasculitis, intraocular inflammation, endophthalmitis or choroidal neovascularization, is a notable advantage compared to some existing GA therapies.
• The durable and statistically significant (p=0.005) improvement in visual function (LLVA) in all evaluable treated subjects at two years in the Phase 1/2 OCU400 clinical trial for RP is a promising result compared to the natural progression of the disease.

Stakeholder Impact

• Shareholders may benefit from the potential for future BLA filings and commercialization of new therapies.
• Patients with blindness diseases may have access to new treatment options.
• Employees are contributing to the development of innovative therapies.
• The company's success could lead to increased collaboration with study centers and investigators.

Next Steps

• Initiate the Phase 2/3 study for OCU410ST in mid-2025.
• Complete enrollment in the Phase 3 liMeliGhT clinical trial for OCU400 in the first half of 2025.
• Complete 1-year follow up in the first quarter of 2026 for OCU410 Phase 1/2 ArMaDa clinical trial.
• File BLA and MAA submissions for OCU400 in mid-2026.
• Target BLA submission for OCU410ST by 2027.
• Target a BLA filing for OCU410 in 2028.

Key Dates